Aim: To improve and validate an analytical method based on liquid chromatography and electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) for the quantitative measurement of ilaprazole and its two metablites in human plasma. Methods: Separation of analytes and the internal standard (IS), omeprazole, was performed on a Thermo HyPURITY C18 column (150×2.1 mm, 5 µm) with a mobile phase consisting of 10 mmol/L ammonium formate water-acetonitrile solution ( Results: The method was linear over the concentration range of 0.23−2400.00 ng/mL for ilaprazole, 0.05−105.00 ng/mL for ilaprazole thiol ether and 0.06−45.00 ng/mL for ilaprazole sulfone. The intra-and inter-day precisions were all less than 15% in terms of relative standard deviation (RSD), and the accuracy was within 15% in terms of relative error (RE) for ilaprazole, ilaprazole sulfone and ilaprazole thiol ether. The lower limit of quantification (LLOQ) was identifiable and reproducible at 0.23, 0.05 and 0.06 ng/mL with acceptable precision and accuracy for ilaprazole, ilaprazole sulfone and ilaprazole thiol ether, respectively. Conclusion: The validated method offered sensitivity and a wide linear concentration range. This method was successfully applied for the evaluation of the pharmacokinetics of ilaprazole and its two metabolites after single oral doses of 5 mg ilaprazole to 12 healthy Chinese volunteers.
Introduction
Ilaprazole[-[(4-methoxy-3-methyl-pyridin-2-yl)methylsulfinyl]-6-pyrrol-1-yl-1H-benzoimidazole, Figure 1 ], a substituted benzimidazole, is a new candidate drug that is an H + /K + -ATPase inhibitor designed for the treatment of gastric ulcers [1, 2] . Ilaprazole was under development by IIYang Pharmacy Co (Seoul, Korea) and has been proven by a series of animal studies to be a potent and safety antiulcer agent. SeungWoon Myung et al found two metabolites of ilaprazole using LC-MS/MS in rat plasma, the major one being ilaprazole sulfone ( Figure 1 ) [3] . Recently, a new metabolite of ilaprazole, ilaprazole thiol ether, was identified ( Figure 1 ). Quantification of drugs in biological matrices by liquid chromatography/tandem mass spectrometry (LC/MS/MS) is becoming an increasingly common technology today due to the improved sensitivity and selectivity of these methods. Li et al reported that ilaprazole was metabolized by CYP3A5 and CYP2C9 in Chinese healthy subjects using a LC-MS/MS method to determine ilaprazole and ilaprazole sulfone concentrations [4] . We now report an improved LC/MS/MS method and have validated the procedure for the simultaneous detection and quantification of ilaprazole, ilaprazole sulfone and ilaprazole thiol ether in human plasma. Furthermore, this method is capable of quantifying ilaprazole, ilaprazole sulfone and ilaprazole thiol ether at concentrations of 0.23 ng/mL, 0.05 and 0.06 ng/mL, respectively. At the same time, it is expected that this method would be efficient in analyzing a large number of plasma samples obtained for pharmacokinetic, bioavailability or bioequivalence studies after administration of therapeutic doses of ilaprazole.
Materials and methods

Materials and reagents
Ilaprazole, ilaprazole sulfone and ilaprazole thiol ether standards were obtained from the Livzon Pharmaceutical Group Inc (purity: 99.1% Zhuhai, China); omeprazole standards were obtained from Sigma Company (purity: 99.5%, USA). Ilaprazole tablets were kindly supplied from Livzon Pharmaceutical Group Inc (Zhuhai, China). HPLC-grade acetonitrile; methanol and methyl tert-butyl ether (MTBE) were purchased from Dikma Comp (Guangzhou, China). HPLC-grade water was from a Milli-Q system (Millipore, USA). All other reagents were of analytical grade.
Instruments
The instrumentation system used in this study consisted of an Agilent 1200 series RPLC (vacuum degasser, binary pump, and thermo stated column compartment) from Agilent Technologies (Palo Alto, CA, USA), and an API4000 triple quadruple mass spectrometer by Applied Biosystems (Foster City, CA, USA) with an electrospray (ESI) Turbo V™ Ion Source. A HyPURITY C18 (150×2.1 mm, 5 µm) column by ThermoHypersil Keystone (Bellefonte, PA) was used. The data was collected and processed using Analyte 1.4.2 software from Applied Biosystems (Foster City, CA, USA).
Chromatographic conditions
The separation was performed on a Thermo HyPURITY C18 column (150 mm×2.1 mm, 5 µm). The mobile phase, consisting of a solution of 10 mmol/L ammonium formate water solution-acetonitrile (50:50, v/v), was pumped at a flow rate of 0.25 mL/min. Prior to the analysis, the column was equilibrated with the mobile phase at a flow rate of 0.25 mL/min for about 15 min. During the analysis, 10 µL of sample was injected by the auto sampler and carried on the analyst column by the mobile phase.
Mass spectrometer conditions
The API4000 triple quadruple mass spectrometer was operated under the positive electrospray ionization mode (ESI + ). The mass spectrometer was tuned by infusion of ilaprazole and its two metabolites (1.0 µg/mL) and omeprazole (1.0 µg/mL) in the mobile phase at a flow rate of 10 µL/min with a syringe pump (Harvard Apparatus, South Natick, MA, USA). The tandem mass spectrometer was tuned to monitor the m/z 367. [5] . The spectra and the proposed patterns of ilaprazole, ilaprazole sulfone, ilaprazole thiol ether and omeprazole fragmentation, as well as a summary of the adjusted MS conditions and the compound-specific MSparameters, are presented in Figure 2 and Table 1 .
Preparation of stock solutions, calibration standard and quality control samples (QC) Stock solutions of ilaprazole, ilaprazole sulfone and ilaprazole thiol ether at the concentrations of 2.40 mg/mL, 4.50 mg/mL, and 1.05 mg/mL, respectively, were prepared in methanol. The internal standard (omeprazole) was also prepared as a stock solution (2.80 mg/mL) in methanol and was further diluted with 10 mmol/L ammonium formate water solution to give a concentration of 280 ng/mL and used for all analyses. Serial calibration curve samples at concentrations of 0.23, 0.47, 3.75, 15.00, 60.00, 300.00, 600.00, 1200.00, and 2400.00 ng/mL of ilaprazole, 0.06, 0.18, 0.70, 2.81, 5.63, 11.30, 45.00 ng/mL of ilaprazole sulfone, and 0.05, 0.10, 0.41, 1.64, 6.56, 26.30 and 105.00 ng/mL of ilaprazole thiol ether were freshly prepared by serially diluting a stock solution with drug-free plasma. The quality control (QC) samples were prepared in the same way at concentrations of 0.23 (LLOQ), 0.47 (low), 15.00 (medium) and 1200.00 ng/mL (high) of ilaprazole, 0.06 (LLOQ), 0.18 (low), 2.81 (medium) and 45.00 ng/mL (high) of ilaprazole sulfone, 0.05 (LLOQ), 0.10 (low), 1.64 (medium) and .00 ng/mL (high) of ilaprazole thiol ether. All plasma samples were stored at -40 °C. Fifty microliters of IS (280 ng/mL) was added to 0.2 mL of calibration curve samples and quality control samples. The further processing of both the calibration curve samples and the quality control samples were the same as described in the following section (section 2.6) for collection and preparation of the samples. All standard stock solutions were prepared once a month and stored at -40 °C [6] .
Sample preparation
All frozen human plasma samples were thawed at room temperature. In order to perform sample extraction, 0.2 mL of the sample (human plasma) was added in a 1.5 mL eppendorf tube (EP), and 100 µL of 50 mmol/L ammonium formate water solution plus 50 µL of 280 ng/mL omeprazole standard solution was added; 0.6 mL of MTBE was subsequently added. The extraction was then performed by vortex-mixing for 2 min, followed by centrifugation of the mixture at11 500×g for 10 min. The organic phase was placed into another EP tube, and evaporated to dryness under a stream of N 2 . The residue was reconstituted in 200 µL of mobile phase solution and10 µL of the mixture was injected into the LC-MS/MS system.
Clinical trial
The developed LC-MS-MS method was applied to determine the plasma concentrations of ilaprazole from a clinical trial study in which 12 healthy male Chinese subjects were enrolled. The subjects ranged in age from 19 to 27 years (22.45±1.91) and weighed between 50.0 and 71 kg (58.29±5.76).
The pharmacokinetic study was approved by the medical Ethics Committee of Hunan Xiangya Hospital. Informed consent was obtained from all subjects after explaining the aims and risks of the study. The doses of ilaprazole chosen for this study were based on findings from preclinical and early clinical studies. Twelve volunteers continuously received 10 mg ilaprzole enteric-coated tablet for 5 days. Blood samples were collected on the fifth day. An indwelling cannula was placed in the other arm for blood sampling. Before sampling, 
Results
Extraction method
The purpose of this study was to develop a simple and inexpensive extraction method that could be readily implemented in monitoring labs. Therefore, our work focused on the use of liquid-liquid extraction. Hexane: ethylene chloride, MTBE, chloroform [4] , dichloromethane and ethyl acetate were evaluated as extraction solvents under neutral conditions with 100 mmol/L ammonium formate. The best recovery was observed with chloroform and MTBE as the extraction solvent. Since it can be easily evaporated, MTBE was selected as the extraction solvent.
Assay validation
Assay validation was performed in accordance with current guidelines [7, 8] Representative chromatogram Representative chromatograms of a control double blank sample, a control single blank sample containing 280 ng/mL ISTD, and a 0.23 ng/mL, 0.06 and 0.05 ng/mL ilaprazole, ilaprazole sulfone and ilaprazole thiol ether, respectively, plasma standard (LLOQ) are shown in Figure 3A -3C .
Intraday variability
An assessment of intraday variability was conducted by analyzing standard curve samples in five different lots of human control plasma over the calibration range of 0.23−2400.00 ng/ mL, 0.06-45.00 ng/mL, 0.05-105.00 ng/mL for ilaprazole, Table  2 . The coefficient of variation of the assay was ≤9.5 for all concentrations within the standard curve range, while the assay accuracy was 93.8%-117.2 % of nominal.
Quality control samples
Quality control (QC) samples containing concentrations of 0.23 ng/mL (LLOQ), 0.47 ng/mL (low), 15.00 ng/mL (medium) and 1200.00 ng/mL (high) of ilaprazole, 0.06 ng/mL (LLOQ), 0.18 ng/mL (low), 2.81 ng/mL (medium) and 45.00 ng/mL (high) of ilaprazole sulfone, 0.05 ng/mL (LLOQ), 0.10 ng/ mL (low), 1.64 ng/mL (medium) and 105.00 ng/mL (high) of ilaprazole thiol ether were used. Initial within-day analysis of the QC samples was within 8.3 of nominal with a CV of 9.5 or below (Table 3) .
Inter-day variability of quality control samples Robustness of the described method was demonstrated through inter-day (n=15) analysis of QC samples over a 2-month study span. The average QC accuracy was within 6.52% of nominal and the precision was 4.25 % or below.
Extraction recovery and assessment of the Matrix effect on ionization Extraction recovery and the effect of the sample matrix on www.chinaphar.com Zhou G et al Acta Pharmacologica Sinica npg ionization were evaluated for ilaprazole, ilaprazole sulfone, ilaprazole thiol ether using standard samples prepared at three QC concentrations in five different individual human plasma samples. Recovery of the extraction was determined by comparing the absolute peak areas of the standards in human plasma extracted as described to control plasma extracted in the same manner and then spiked post extraction with the same concentration of the drug and internal standard. Matrix enhancement/suppression of ionization was evaluated by comparing the absolute peak areas of control plasma extracted and then spiked with a known amount of drug, to approximate standards injected directly in the same reconstitution solvent. Results are shown in Table 4 . Based on the intra-day precision results that were obtained using six different lots of control plasma, a relative matrix effect was not expected to affect the assay (Table 4 ). The lack of a relative matrix effect is further illustrated in Table 5 , where an examination of the slopes of the standard curves prepared from five different lots of control plasma shows a precision of 5.086, 11.731, and 5.205 for ilaprzole, ilaprzole sulfone and ilaprazole thiol ether, respectively.
Stability
This method assessed the freeze-thaw, room temperature, processed sample stability, short-term and long-term stability of ilaprazole and its metabolites. The results showed that the ilaprazole and its two metabolites were stable in all of the above experimental conditions.
Clinical sample analysis
Human plasma samples were analyzed following administration of oral 10 mg doses of ilaprazole. A representative postdose chromatogram from 3 h after administration of a 10 mg dose is shown in Figure 3C . Mean (n=12 subjects) plasma a Extraction recovery was calculated by dividing the mean peak area of analyte spiked before extraction by the respective mean peak area of analyte spiked into extracts of control plasma and multiplying by 100. b Matrix effect was calculated by dividing the mean peak area of analyte spiked into control plasma extracts by the mean peak area of the neat analyte standard and multiplying by 100. c (n=15).
concentration vs time profiles of ilaprazole, ilaprazole sulfone, and ilaprazole thiol ether after continuous oral administration of 10 mg dose are shown in Figure 4 .
Discussion and conclusion
The LC-MS-MS method had been reported in the literature [3, 4] ; however, this is the first time that the simultaneous detection of ilaprazole, ilaprazole sulfone and ilaprazole thiol ether has been performed using this method. The C max of ilaprazole from Figure 4 was different from the C max and AUC determined in a previous study from our lab [4] . From the individual data, we found that the C max values of two healthy volunteers were higher than those of the other volunteers. When we exclude the data from these two volunteers, the C max and AUC values are consistent with those found in the previous study [6] . Further study of these two outlier samples will be conducted by our lab. A rapid and specific liquid chromatograph tandem mass spectrometric method has been improved and validated for the quantitative measurement of ilaprazole and its two metabolites. It has been successfully applied to characterize the pharmacokinetics of ilaprazole and its two metablites in Chinese healthy volunteers.
